A Phase 2 interventional study of ABX464 and Placebo in HIV Infection, sponsored by Abivax S.A.. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in HIV Infections with a site in Belgium — 3 open to participants now, 8 under way, 3 of them phase 3. HIV Infections · Belgium.
Among the 97 studies in HIV Infections with a site in Belgium, this one is the 73rd largest by enrollment of the 80 interventional ones that give a count, is one of 3 that started in 2016, is one of 11 in phase 2, and was the 71st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →3 of the 97 studies in HIV Infections with a site in Belgium are open now. Recruiting first, the newest first:
ViiV Healthcare · Sites in Belgium, United States, Argentina and 11 more countries
Ages 18+
Casper Rokx · Sites in Belgium, France, Germany and 7 more countries
Ages 18+ · Healthy volunteers
Radboud University Medical Center · Sites in Belgium, Germany, Ireland and 4 more countries
Ages 18+ · Women only
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 17 · Phase 3 50 · Phase 4 4
First in 2000; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 439 across the 80 interventional studies, 363 across the 12 observational. Of the 84 that completed or were terminated, 41 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 97 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 2 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00825929Radboud University Medical CenterPharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. | 2026-12 |
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07202546ViiV HealthcareA Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) | 2027-10-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 97 studies in HIV Infections with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a placebo-controlled study aimed at assessing the safety of ABX464 administered at 50 mg and 150 mg o.d. versus placebo in HIV infected patients who are treated with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI).
This study is a placebo-controlled study aimed at assessing the safety of ABX464 administered at 50 mg o.d. and 150 mg versus placebo in HIV infected patients who are treated with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI). Eligible patients should be treated with darunavir + ritonavir or darunavir + cobicistat as monotherapy for at least 8 weeks prior to baseline. Patients should be fully suppressed (\< 50 copies/mL) at least during the last 6 months prior to enrolment.
Upon screening visit, eligible patients will continue DRV/RTV or DRV/COBI single regimen given respectively at 800 mg of darunavir with 100 mg of ritonavir or 150 mg of cobicistat once a day with food in the morning.
At Day 0, study drug (ABX464 or its matching placebo) will be added on top of this background therapy for the next 28 days. ABX464 or its matching placebo will be given once a day at 50 mg or 150 mg.
At day 29, DRV/RTV or DRV/COBI and ABX464 or its matching placebo (i.e. all treatments) will be stopped. The viral load will be monitored twice a week during the first three weeks and weekly during the next weeks. In case of Viral Rebound (VR; defined below), ART will be resumed.
A 3:1 randomization ratio will be applied meaning that, per treatment block, 3 patients will receive ABX464 on top of DRV/RTV or DRV/COBI and 1 patient will receive placebo on top of DRV/RTV or DRV/COBI.
Dose limiting toxicity (DLT) is defined as a grade 3 or higher adverse event as defined by the "Division of AIDS table for grading the severity of adult and pediatric adverse events" (including signs/symptoms, lab toxicities and/or clinical events) considered by the Data Safety Monitoring Board as probably or definitely related to study treatment.
If more than 2 DLTs occur during the treatment period of the first four treated patients, then the enrolment of additional patients will be stopped. In addition, in case of a life threatening (grade 4) adverse reaction enrolment and treatment of ongoing patients will be immediately discontinued. In both cases, enrolment will only be resumed upon the decision of the sponsor if the Data Safety Monitoring Board can conclude that the causality of the event was unrelated or unlikely related to study treatment.
Thorough pharmacokinetics analysis will be performed to characterize potential drug-drug interactions between ABX464 and DRV/RTV-COBI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fixed dose of ABX464 50mg once daily given during 28 days in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
Drug: ABX464
Matching placebo of ABX464 given at 50mg once daily in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
Drug: Placebo
50 mg or 150mg once daily for 28 days
ABX464 matching placebo
Number of Participants With Adverse Events
Patients who had received at least one dose of the study drug, and who had at least one baseline value. An AE was classified as a TEAE if it started, or increased in severity, on or after the first date and time of medication dosing (from Day 1 up to Day 28). Any AE which occurred after Day 28 was classified as post-treatment-emergent. Events were graded according to the "Division of AIDS table for grading the severity of adult and pediatric adverse events" (Version 2.0 November 2014).
Time frame: Up to 4 months
Time to Viral Rebound
Time To Viral Rebound is defined as the time between treatment stop (i.e. day 29) and viral rebound detection
Time frame: Up to 3 months
| Milestone | ABX464 50mg | ABX464 150mg | ABX464 Matching Placebo |
|---|---|---|---|
| Started | 6 | 16 | 8 |
| Completed | 5 | 14 | 7 |
| Not completed | 1 | 2 | 1 |
Patients who had received at least one dose of the study drug, and who had at least one baseline value. An AE was classified as a TEAE if it started, or increased in severity, on or after the first date and time of medication dosing (from Day 1 up to Day 28). Any AE which occurred after Day 28 was classified as post-treatment-emergent. Events were graded according to the "Division of AIDS table for grading the severity of adult and pediatric adverse events" (Version 2.0 November 2014).
| Participants | ABX464 50mg | ABX464 150mg | ABX464 Matching Placebo |
|---|---|---|---|
| Any AE | 5 | 15 | 7 |
| Any TEAE | 4 | 15 | 3 |
| Any post-TEAE | 4 | 6 | 4 |
| Any serious AE | 0 | 0 | 1 |
| Any severe AE | 0 | 1 | 0 |
| AE leading to death | 0 | 0 | 0 |
Time To Viral Rebound is defined as the time between treatment stop (i.e. day 29) and viral rebound detection
| days | ABX464 50mg | ABX464 150mg | ABX464 Matching Placebo |
|---|---|---|---|
| Time to Viral Rebound | 17.2 ± 3.4 | 14.4 ± 7.4 | 14.4 ± 7.3 |
Collected over Up to 4 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABX464 50mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| ABX464 150mg | 0/16 (0%) | 1/16 (6.3%) | 15/16 (93.8%) |
| ABX464 Matching Placebo | 0/8 (0%) | 1/8 (12.5%) | 7/8 (87.5%) |
| Event | ABX464 50mg | ABX464 150mg | ABX464 Matching Placebo |
|---|---|---|---|
| vagal faintnessNervous system disorders | 0/6 | 0/16 | 1/8 |
| FatigueGeneral disorders | 0/6 | 1/16 | 0/8 |
| Event | ABX464 50mg | ABX464 150mg | ABX464 Matching Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 2/6 | 5/16 | 0/8 |
| Back PainMusculoskeletal and connective tissue disorders | 0/6 | 5/16 | 0/8 |
| Abdominal Pain UpperGastrointestinal disorders | 0/6 | 4/16 | 0/8 |
| NasopharyngitisInfections and infestations | 0/6 | 0/16 | 2/8 |
| Abdominal PainGastrointestinal disorders | 0/6 | 3/16 | 0/8 |
| DiarrheaGastrointestinal disorders | 1/6 | 3/16 | 0/8 |
| FatigueGeneral disorders | 0/6 | 3/16 | 0/8 |
| Influenza Like IllnessGeneral disorders | 1/6 | 1/16 | 0/8 |
| ContusionInjury, poisoning and procedural complications | 1/6 | 0/16 | 0/8 |
| ScarInjury, poisoning and procedural complications | 1/6 | 0/16 | 0/8 |
Patients who had received at least one dose of the study drug, and who had at least one baseline value.
| Age, Categorical(Participants) | ABX464 50mg | ABX464 150mg | ABX464 Matching Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 16 | 8 | 30 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | ABX464 50mg | ABX464 150mg | ABX464 Matching Placebo | Total |
|---|---|---|---|---|
| Mean | 45.2 ± 3.5 | 38.4 ± 10.4 | 48.3 ± 8.5 | 42.4 ± 9.8 |
| Sex: Female, Male(Participants) | ABX464 50mg | ABX464 150mg | ABX464 Matching Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 1 | 0 | 1 |
| Male | 6 | 15 | 8 | 29 |
| Race (NIH/OMB)(Participants) | ABX464 50mg | ABX464 150mg | ABX464 Matching Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 2 |
| White | 6 | 14 | 7 | 27 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | ABX464 50mg | ABX464 150mg | ABX464 Matching Placebo | Total |
|---|---|---|---|---|
| Belgium | 3 | 10 | 4 | 17 |
| France | 0 | 1 | 1 | 2 |
| Spain | 3 | 5 | 3 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2016, a primary completion of Aug 2017 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2024, 7 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464